Evidence map›Paper›PMID 29882126›Full record

ArticleNeurochemical research2018

Irisin Peptide Protects Brain Against Ischemic Injury Through Reducing Apoptosis and Enhancing BDNF in a Rodent Model of Stroke.

Yasin Asadi, Fazel Gorjipour, Sedigheh Behrouzifar, Abedin Vakili

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 109 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Therapeutic Potential of Irisin in Neurodegenerative Diseases.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Irisin deficiency exacerbates cardiac dysfunction and enhances hemorrhage injury in hemorrhage/resuscitation.American journal of physiology. Regulatory, integrative and comparative physiology · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Impact of Exercise Intensity on Cerebral BDNF Levels: Role of FNDC5/Irisin.International journal of molecular sciences · 2024
    Article
  20. FNDC5/Irisin in dementia and cognitive impairment: update and novel perspective.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yasin AsadiResearch Center and Department of Physiology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Fazel GorjipourPhysiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Sedigheh BehrouzifarResearch Center and Department of Physiology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Abedin VakiliResearch Center and Department of Physiology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran. Ab.vakili@yahoo.com.ORCID http://orcid.org/0000-0002-4269-9978
Semnan University of Medical Sciences · IRIran University of Medical Sciences · IR

Funding

Vice Chancellor for Research of the Semnan University of Medical Sciences 917
6 · The paper itself

Abstract

Evidence has shown therapeutic potential of irisin in cerebral stroke. The present study aimed to assess the effects of recombinant irisin on the infarct size, neurological outcomes, blood-brain barrier (BBB) permeability, apoptosis and brain-derived neurotrophic factor (BDNF) expression in a mouse model of stroke. Transient focal cerebral ischemia was established by middle cerebral artery occlusion (MCAO) for 45 min and followed reperfusion for 23 h in mice. Recombinant irisin was administrated at doses of 0.1, 0.5, 2.5, 7.5, and 15 µg/kg, intracerebroventricularly (ICV), on the MCAO beginning. Neurological outcomes, infarct size, brain edema and BBB permeability were evaluated by modified neurological severity score (mNSS), 2,3,5-triphenyltetrazolium chloride (TTC) staining and Evans blue (EB) extravasation methods, respectively, at 24 h after ischemia. Apoptotic cells and BDNF protein were detected by TUNEL assay and immunohistochemistry techniques. The levels of Bcl-2, Bax and caspase-3 proteins were measured by immunoblotting technique. ICV irisin administration at doses of 0.5, 2.5, 7.5 and 15 µg/kg, significantly reduced infarct size, whereas only in 7.5 and 15 µg/kg improved neurological outcome (P < 0.001). Treatment with irisin (7.5 µg/kg) reduced brain edema (P < 0.001) without changing BBB permeability (P > 0.05). Additionally, irisin (7.5 µg/kg) significantly diminished apoptotic cells and increased BDNF immunoreactivity in the ischemic brain cortex (P < 0.004). Irisin administration significantly downregulated the Bax and caspase-3 expression and upregulated the Bcl-2 protein. The present study indicated that irisin attenuates brain damage via reducing apoptosis and increasing BDNF protein of brain cortex in the experimental model of stroke in mice.

Indexed as

AnimalsApoptosisbcl-2-Associated X ProteinBlood-Brain BarrierBrain-Derived Neurotrophic FactorBrain EdemaCaspase 3Dose-Response Relationship, DrugDown-RegulationFibronectinsInfarction, Middle Cerebral ArteryMaleMiceProto-Oncogene Proteins c-bcl-2Recombinant ProteinsTime FactorsBax protein, mousebcl-2-Associated X ProteinBcl2 protein, mouseBdnf protein, mouseBrain-Derived Neurotrophic FactorCasp3 protein, mouseCaspase 3FibronectinsFNDC5 protein, mouseProto-Oncogene Proteins c-bcl-2Recombinant ProteinsApoptosisBDNFBlood–brain barrier permeabilityBrain edemaFocal cerebral ischemiaImmunohistochemistryInfarct sizeMice

Identifiers

PMID29882126
OpenAlexW2806230570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.